Skip to main content
Top
Published in: International Cancer Conference Journal 2/2024

14-02-2024 | Cytostatic Therapy | Case report - Chemotherapy

Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy

Authors: Hiroha Tokui, Hideaki Yahata, Yasuhiro Okabe, Naomi Magarifuchi, Shoji Maenohara, Kazuhisa Hachisuga, Hiroshi Tomonobe, Keisuke Kodama, Hiroshi Yagi, Masafumi Yasunaga, Ichiro Onoyama, Kazuo Asanoma, Yoshinao Oda, Masafumi Nakamura, Kiyoko Kato

Published in: International Cancer Conference Journal | Issue 2/2024

Login to get access

Abstract

Adult granulosa cell tumors are rare, accounting for only 3–5% of all ovarian tumors. Adult granulosa cell tumors have late recurrences, for which complete resection is an effective option. We report a patient who underwent complete resection of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy. A 72-year-old woman underwent primary surgery for an adult granulosa cell tumor 19 years earlier. A huge recurrent tumor, 11 × 10 cm in size, was noted to elevate the hepatic hilum, inferior vena cava, and right renal vein. The recurrent tumor was too large to resect, thus paclitaxel and carboplatin were administered as neoadjuvant chemotherapy. The tumor shrank to 6 × 5 cm after 6 cycles of chemotherapy, then complete tumor extirpation with resection of the right kidney and temporary scission of inferior vena cava was performed. The patient was alive and well without evidence of a recurrence 1 y postoperatively. Paclitaxel and carboplatin, as neoadjuvant chemotherapy, might be an effective treatment option to achieve complete reduction surgery. This is the first report demonstrating the effectiveness of paclitaxel and carboplatin for huge recurrent adult granulosa cell tumor.
Literature
1.
go back to reference Färkkilä A, Haltia UM, Tapper J et al (2017) Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 49:435–447CrossRefPubMed Färkkilä A, Haltia UM, Tapper J et al (2017) Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med 49:435–447CrossRefPubMed
2.
3.
go back to reference Hauptmann S, Friedrich K, Redline R et al (2017) Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 470(2):125–142CrossRefPubMed Hauptmann S, Friedrich K, Redline R et al (2017) Ovarian borderline tumors in the 2014 WHO classification: evolving concepts and diagnostic criteria. Virchows Arch 470(2):125–142CrossRefPubMed
4.
go back to reference Mangili G, Sigismondi C, Frigerio L et al (2013) Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol 130:38–42CrossRefPubMed Mangili G, Sigismondi C, Frigerio L et al (2013) Recurrent granulosa cell tumors (GCTs) of the ovary: a MITO-9 retrospective study. Gynecol Oncol 130:38–42CrossRefPubMed
5.
go back to reference Lee YK, Park NH, Kim JW et al (2008) Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18:642–647CrossRefPubMed Lee YK, Park NH, Kim JW et al (2008) Characteristics of recurrence in adult-type granulosa cell tumor. Int J Gynecol Cancer 18:642–647CrossRefPubMed
6.
go back to reference Yang TM, Chen CH (2022) Early-stage granulosa cell tumor with pelvic recurrence and lung metastasis 16 years later: A case report and review of the literature. Taiwan J Obstet Gynecol 61:118–121CrossRefPubMed Yang TM, Chen CH (2022) Early-stage granulosa cell tumor with pelvic recurrence and lung metastasis 16 years later: A case report and review of the literature. Taiwan J Obstet Gynecol 61:118–121CrossRefPubMed
7.
go back to reference East N, Alobaid A, Goffin F et al (2005) Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 27:363–364CrossRefPubMed East N, Alobaid A, Goffin F et al (2005) Granulosa cell tumour: a recurrence 40 years after initial diagnosis. J Obstet Gynaecol Can 27:363–364CrossRefPubMed
8.
go back to reference Plett H, Ricciardi E, Vacaru V et al (2023) Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence. Int J Gynecol Cancer 33:734–740CrossRefPubMed Plett H, Ricciardi E, Vacaru V et al (2023) Adult ovarian granulosa cell tumors: analysis of outcomes and risk factors for recurrence. Int J Gynecol Cancer 33:734–740CrossRefPubMed
9.
go back to reference Inzani F, Santoro A, Travaglino A et al (2022) Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis. Arch Gynecol Obstet 306:315–321CrossRefPubMed Inzani F, Santoro A, Travaglino A et al (2022) Prognostic predictors in recurrent adult granulosa cell tumors of the ovary: a systematic review and meta-analysis. Arch Gynecol Obstet 306:315–321CrossRefPubMed
10.
go back to reference Alhusaini H, Elshenawy MA, Badran A et al (2022) Adult-type ovarian granulosa cell tumour: Treatment outcomes from a single-institution experience. Cureus 14:e31045PubMedPubMedCentral Alhusaini H, Elshenawy MA, Badran A et al (2022) Adult-type ovarian granulosa cell tumour: Treatment outcomes from a single-institution experience. Cureus 14:e31045PubMedPubMedCentral
11.
go back to reference Thomakos N, Biliatis I, Koutroumpa I et al (2016) Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary. Arch Gynecol Obstet 294:1031–1036CrossRefPubMed Thomakos N, Biliatis I, Koutroumpa I et al (2016) Prognostic factors for recurrence in early stage adult granulosa cell tumor of the ovary. Arch Gynecol Obstet 294:1031–1036CrossRefPubMed
12.
go back to reference Sehouli J, Drescher FS, Mustea A et al (2004) Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 24:1223–1229PubMed Sehouli J, Drescher FS, Mustea A et al (2004) Granulosa cell tumor of the ovary: 10 years follow-up data of 65 patients. Anticancer Res 24:1223–1229PubMed
13.
go back to reference Homesley HD, Bundy BN, Hurteau JA et al (1999) Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic Oncology Group study. Gynecol Oncol 72:131–137CrossRefPubMed Homesley HD, Bundy BN, Hurteau JA et al (1999) Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic Oncology Group study. Gynecol Oncol 72:131–137CrossRefPubMed
14.
go back to reference Brown J, Shvartsman HS, Deavers MT et al (2005) The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 97:489–496CrossRefPubMed Brown J, Shvartsman HS, Deavers MT et al (2005) The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol 97:489–496CrossRefPubMed
15.
go back to reference Brown J, Shvartsman HS, Deavers MT et al (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22:3517–3523CrossRefPubMed Brown J, Shvartsman HS, Deavers MT et al (2004) The activity of taxanes in the treatment of sex cord-stromal ovarian tumors. J Clin Oncol 22:3517–3523CrossRefPubMed
Metadata
Title
Complete reduction surgery of a huge recurrent adult granulosa cell tumor after neoadjuvant chemotherapy
Authors
Hiroha Tokui
Hideaki Yahata
Yasuhiro Okabe
Naomi Magarifuchi
Shoji Maenohara
Kazuhisa Hachisuga
Hiroshi Tomonobe
Keisuke Kodama
Hiroshi Yagi
Masafumi Yasunaga
Ichiro Onoyama
Kazuo Asanoma
Yoshinao Oda
Masafumi Nakamura
Kiyoko Kato
Publication date
14-02-2024
Publisher
Springer Nature Singapore
Published in
International Cancer Conference Journal / Issue 2/2024
Electronic ISSN: 2192-3183
DOI
https://doi.org/10.1007/s13691-024-00659-5

Other articles of this Issue 2/2024

International Cancer Conference Journal 2/2024 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine